NASDAQ:WVE WAVE Life Sciences Q2 2026 Earnings Report $5.81 +0.03 (+0.52%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.78 -0.03 (-0.52%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast WAVE Life Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.31Beat/MissN/AOne Year Ago EPSN/AWAVE Life Sciences Revenue ResultsActual RevenueN/AExpected Revenue$7.45 millionBeat/MissN/AYoY Revenue GrowthN/AWAVE Life Sciences Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateThursday, July 30, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile WAVE Life Sciences Earnings HeadlinesWave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On SalesJuly 24 at 1:07 AM | finance.yahoo.comWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026July 23 at 9:00 AM | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.July 25 at 1:00 AM | Chaikin Analytics (Ad)WAVE Life Sciences (WVE) to Release Quarterly Earnings on ThursdayJuly 23 at 2:26 AM | americanbankingnews.comWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for RedomiciliationJuly 7, 2026 | globenewswire.comWave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM TrialJune 30, 2026 | insidermonkey.comSee More WAVE Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like WAVE Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on WAVE Life Sciences and other key companies, straight to your email. Email Address About WAVE Life SciencesWAVE Life Sciences (NASDAQ:WVE) is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines. The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas. WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions. Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.View WAVE Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
